J. Mark Braughler
Nessuna posizione attualmente
Profilo
J.
Mark Braughler worked as a Director at Kylin Therapeutics, Inc. and as a Vice President-Translational Medicine at Precigen, Inc. He received his undergraduate degree from the University of Pittsburgh in 1976.
Precedenti posizioni note di J. Mark Braughler
Società | Posizione | Fine |
---|---|---|
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Direttore/Membro del Consiglio | 01/07/2013 |
PRECIGEN, INC. | Corporate Officer/Principal | - |
Formazione di J. Mark Braughler
University of Pittsburgh | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
PRECIGEN, INC. | Health Technology |
Aziende private | 1 |
---|---|
Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kylin Therapeutics, Inc., a cutting-edge biotechnology company, employs a revolutionary RNA nanoparticle technology platform called 'pRNA' to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies. The formation of Kylin Therapeutics Inc., is a result of a joint partnership between IN-vivo Ventures, LLC, and Golden Pine Ventures, LLC. Together, these two companies can leverage their alliance partners and strong Board of Directors to ensure Kylin's success. A lean, cross-functional management team is set to effect early stage success. This team provides the essential ingredients to develop and promote Kylin to the next level. It is the goal of this team to provide early stage validation and market traction to attract world-class operational management with relevant credentials, track records, and operational experience. | Commercial Services |
- Borsa valori
- Insiders
- J. Mark Braughler